Session » 3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

Date: Sunday, October 21, 2018

Time: 2:30PM-4:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 875

Anti-Calreticulin Antibody – a Novel Antibody in Patients with Idiopathic Inflammatory Myopathies and Its Association with Malignancy

2:30PM-4:00PM: Abstract Number: 876

Dermatomyositis Skin Shares Type I Interferon Overlap with Cutaneous Lupus but Displays Many Unique Expression Changes That May Serve As Biomarkers for Skin Disease

2:30PM-4:00PM: Abstract Number: 878

IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome

2:30PM-4:00PM: Abstract Number: 879

IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis

2:30PM-4:00PM: Abstract Number: 877

Serum Krebs Von Den Lungen-6 Is a Useful Biomarker for Assessing Activity of Myositis-Associated Interstitial Lung Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].